Servier Acquires Day One Biopharmaceuticals for $2.5 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy DAWN?
Source: PRnewswire
- Acquisition Overview: Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash, totaling approximately $2.5 billion, with the transaction expected to close in Q2 2026, reinforcing Servier's position in oncology targeted therapies.
- Strategic Alignment: This acquisition aligns with Servier's 2030 ambition to develop innovative treatments for patients with high unmet medical needs, enhancing its oncology pipeline with programs ranging from early-stage to phase 3.
- Combining Expertise: The merger of Day One's scientific expertise with Servier's established global capabilities advances a shared commitment to delivering innovative solutions for patients worldwide, particularly in the rare cancer treatment space.
- Patient-First Philosophy: Day One CEO Jeremy Bender emphasized that Servier's dedication to the rare disease community aligns with Day One's mission, ensuring the continuation of a patient-first mindset that drives their commitment to the communities they serve.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DAWN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DAWN
Wall Street analysts forecast DAWN stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.330
Low
16.00
Averages
22.29
High
29.00
Current: 21.330
Low
16.00
Averages
22.29
High
29.00
About DAWN
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Monteverde Law Firm Investigates Multiple Biopharmaceutical Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the sale of Day One Biopharmaceuticals, Inc., where shareholders are expected to receive $21.50 per share in cash, providing substantial returns and enhancing market confidence in the biopharmaceutical sector.
- Merger Transaction Analysis: The merger between CECO Environmental Corp. and Thermon Group Holdings, Inc. is expected to grant CECO shareholders approximately 62.5% ownership in the combined company, significantly boosting CECO's market position in the environmental sector.
- Cash Acquisition Opportunity: Enhabit Inc.'s sale to Kinderhook Industries, LLC is projected to yield $13.80 per share for shareholders, reflecting a direct cash return that indicates market confidence in Enhabit's future growth prospects.
- Capital Investment Outlook: The transaction involving KORE Group Holdings, Inc. with Searchlight Capital Partners, L.P. and Abry Partners is expected to provide shareholders with $9.25 per share, offering stable cash flow and enhancing KORE's attractiveness in the capital markets.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these stocks.
- Market Dynamics Overview: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the affected stocks.
- Investor Focus: For those considering buying DAWN stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This rating change information is provided by Benzinga, highlighting the critical role analysts play in the market by helping investors gain a more comprehensive view of market conditions.
See More
Investor Rights Law Firm Investigates Transactions
- Potential Violation Investigation: Halper Sadeh LLC is investigating transactions involving Day One Biopharmaceuticals, Inc. selling to Servier for $21.50 per share and Talkspace, Inc. selling to Universal Health Services for $5.25 per share, which may involve breaches of fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm encourages shareholders to reach out to discuss their rights and options, promising legal consultations at no cost to ensure fair treatment in the transactions.
- Legal Fee Arrangement: Halper Sadeh LLC operates on a contingency fee basis, meaning shareholders will not have to pay upfront legal fees or expenses, thereby reducing their financial risk in pursuing claims.
- Global Investor Representation: The firm represents investors worldwide, focusing on combating securities fraud and corporate misconduct, and has successfully recovered millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
Day One Biopharmaceuticals Soars 100% on $2.5 Billion Acquisition
- Acquisition Overview: Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) announced its acquisition by France-based Servier for $2.5 billion, with a tender offer of $21.50 per share representing a 68% upside from the pre-announcement price of $12.78, indicating strong market confidence in the deal.
- Stock Performance: Following the acquisition announcement, Day One's stock surged 100% week-on-week, reflecting investor optimism about the company's future prospects and highlighting ongoing interest in the biopharmaceutical sector.
- Transaction Completion Timeline: The deal is expected to close in the second quarter of the year, subject to customary closing conditions including shareholder approval, providing investors with a clear timeline for the transaction.
- Strategic Implications: CEO Jeremy Bender noted that joining Servier offers a unique opportunity to enhance their leading program in pediatric low-grade glioma, emphasizing Servier's commitment to rare diseases aligns with Day One's mission to serve patients with life-threatening conditions.
See More
Day One Biopharmaceuticals to Merge with Servier for $2.5 Billion
- Merger Agreement: Day One Biopharmaceuticals has entered into a definitive agreement with France-based Servier, which will acquire Day One's shares at $21.50 each, totaling $2.5 billion, representing a 68% premium over the latest closing price, indicating strong market confidence in the deal.
- Stock Surge: Following the merger announcement, Day One's stock soared to an intra-day high of $21.23 before closing up 65.88% at $21.20, reflecting investor optimism regarding the company's future growth potential.
- Expected Closing Timeline: The companies anticipate closing the transaction in the second quarter of the year, subject to customary closing conditions, providing investors with a clear timeline that enhances market confidence.
- Strategic Importance: CEO Jeremy Bender noted that Servier's successful track record in rare cancers and commitment to targeted therapies make it the ideal partner for Day One, further extending its reach in pediatric low-grade glioma and preserving its patient-first approach.
See More
U.S. Stocks Decline on Weak Jobs Report
- Weak Employment Data: The U.S. Bureau of Labor Statistics reported a decrease of 92,000 jobs in February, with the unemployment rate rising by 10 basis points to 4.4%, intensifying market concerns about potential stagflation and leading to widespread stock declines.
- Surging Oil Prices: Oil prices surged past $90 due to ongoing Middle East conflicts, marking the largest weekly increase since 2020; while this boosted energy stocks, it negatively impacted most other equities as investors reassessed the likelihood of sustained inflation.
- Biotech Stock Surge: Day One Biopharmaceuticals saw a 65.88% increase in stock price following a buyout agreement with international pharmaceutical group Servier, with a cash acquisition price of $21.50 per share, totaling an equity value of approximately $2.5 billion, indicating strong market interest in the biotech sector.
- Market Sentiment Shift: Despite a slight gain of 0.84% in energy stocks like Diamondback Energy, the overall market sentiment remains risk-averse, with investors adopting a cautious outlook on future economic prospects amid the dual pressures of weak employment data and rising oil prices.
See More
Monteverde Law Firm Investigates Multiple Biopharmaceutical Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the sale of Day One Biopharmaceuticals, Inc., where shareholders are expected to receive $21.50 per share in cash, providing substantial returns and enhancing market confidence in the biopharmaceutical sector.
- Merger Transaction Analysis: The merger between CECO Environmental Corp. and Thermon Group Holdings, Inc. is expected to grant CECO shareholders approximately 62.5% ownership in the combined company, significantly boosting CECO's market position in the environmental sector.
- Cash Acquisition Opportunity: Enhabit Inc.'s sale to Kinderhook Industries, LLC is projected to yield $13.80 per share for shareholders, reflecting a direct cash return that indicates market confidence in Enhabit's future growth prospects.
- Capital Investment Outlook: The transaction involving KORE Group Holdings, Inc. with Searchlight Capital Partners, L.P. and Abry Partners is expected to provide shareholders with $9.25 per share, offering stable cash flow and enhancing KORE's attractiveness in the capital markets.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these stocks.
- Market Dynamics Overview: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the affected stocks.
- Investor Focus: For those considering buying DAWN stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This rating change information is provided by Benzinga, highlighting the critical role analysts play in the market by helping investors gain a more comprehensive view of market conditions.
See More
Investor Rights Law Firm Investigates Transactions
- Potential Violation Investigation: Halper Sadeh LLC is investigating transactions involving Day One Biopharmaceuticals, Inc. selling to Servier for $21.50 per share and Talkspace, Inc. selling to Universal Health Services for $5.25 per share, which may involve breaches of fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm encourages shareholders to reach out to discuss their rights and options, promising legal consultations at no cost to ensure fair treatment in the transactions.
- Legal Fee Arrangement: Halper Sadeh LLC operates on a contingency fee basis, meaning shareholders will not have to pay upfront legal fees or expenses, thereby reducing their financial risk in pursuing claims.
- Global Investor Representation: The firm represents investors worldwide, focusing on combating securities fraud and corporate misconduct, and has successfully recovered millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
Day One Biopharmaceuticals Soars 100% on $2.5 Billion Acquisition
- Acquisition Overview: Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) announced its acquisition by France-based Servier for $2.5 billion, with a tender offer of $21.50 per share representing a 68% upside from the pre-announcement price of $12.78, indicating strong market confidence in the deal.
- Stock Performance: Following the acquisition announcement, Day One's stock surged 100% week-on-week, reflecting investor optimism about the company's future prospects and highlighting ongoing interest in the biopharmaceutical sector.
- Transaction Completion Timeline: The deal is expected to close in the second quarter of the year, subject to customary closing conditions including shareholder approval, providing investors with a clear timeline for the transaction.
- Strategic Implications: CEO Jeremy Bender noted that joining Servier offers a unique opportunity to enhance their leading program in pediatric low-grade glioma, emphasizing Servier's commitment to rare diseases aligns with Day One's mission to serve patients with life-threatening conditions.
See More
Day One Biopharmaceuticals to Merge with Servier for $2.5 Billion
- Merger Agreement: Day One Biopharmaceuticals has entered into a definitive agreement with France-based Servier, which will acquire Day One's shares at $21.50 each, totaling $2.5 billion, representing a 68% premium over the latest closing price, indicating strong market confidence in the deal.
- Stock Surge: Following the merger announcement, Day One's stock soared to an intra-day high of $21.23 before closing up 65.88% at $21.20, reflecting investor optimism regarding the company's future growth potential.
- Expected Closing Timeline: The companies anticipate closing the transaction in the second quarter of the year, subject to customary closing conditions, providing investors with a clear timeline that enhances market confidence.
- Strategic Importance: CEO Jeremy Bender noted that Servier's successful track record in rare cancers and commitment to targeted therapies make it the ideal partner for Day One, further extending its reach in pediatric low-grade glioma and preserving its patient-first approach.
See More
U.S. Stocks Decline on Weak Jobs Report
- Weak Employment Data: The U.S. Bureau of Labor Statistics reported a decrease of 92,000 jobs in February, with the unemployment rate rising by 10 basis points to 4.4%, intensifying market concerns about potential stagflation and leading to widespread stock declines.
- Surging Oil Prices: Oil prices surged past $90 due to ongoing Middle East conflicts, marking the largest weekly increase since 2020; while this boosted energy stocks, it negatively impacted most other equities as investors reassessed the likelihood of sustained inflation.
- Biotech Stock Surge: Day One Biopharmaceuticals saw a 65.88% increase in stock price following a buyout agreement with international pharmaceutical group Servier, with a cash acquisition price of $21.50 per share, totaling an equity value of approximately $2.5 billion, indicating strong market interest in the biotech sector.
- Market Sentiment Shift: Despite a slight gain of 0.84% in energy stocks like Diamondback Energy, the overall market sentiment remains risk-averse, with investors adopting a cautious outlook on future economic prospects amid the dual pressures of weak employment data and rising oil prices.
See More
